Tela Bio Inc Total Liabilities
Tela Bio Inc total liabilities. Based on the latest financial reports, Tela Bio Inc (TELA) has total liabilities worth $75.60 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Tela Bio Inc (TELA) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tela Bio Inc (2017–2025)
Total liabilities of Tela Bio Inc from 2017 to 2025. This chart illustrates how Tela Bio Inc's total liabilities have evolved over time, based on quarterly financial data.
Tela Bio Inc Competitors by Total Liabilities
The table below lists competitors of Tela Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Woory Industrial Co. Ltd
KQ:215360
|
Korea | ₩248.74 Billion |
|
NBI Bearings Europe S.A.
MC:NBI
|
Spain | €78.46 Million |
|
INFOMARK Co. Ltd
KQ:175140
|
Korea | ₩18.78 Billion |
|
Hammer Metals Ltd
AU:HMX
|
Australia | AU$1.77 Million |
|
S&S Power Switchgears Limited
NSE:S&SPOWER
|
India | Rs-892.36 Million |
|
IBKS No2 SPAC
KQ:204840
|
Korea | ₩29.11 Billion |
|
Beaconsmind AG
PA:MLBMD
|
France | €1.90 Million |
|
TAEYANG Corporation
KQ:053620
|
Korea | ₩34.18 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Tela Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Tela Bio Inc.
Liquidity & Leverage Metrics
Tela Bio Inc Total Liabilities Ratios Explained
Tela Bio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tela Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tela Bio Inc (2017–2025)
The table below shows the annual total liabilities of Tela Bio Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $75.11 Million | +27.58% |
| 2024-12-31 | $58.87 Million | -0.51% |
| 2023-12-31 | $59.17 Million | +10.49% |
| 2022-12-31 | $53.55 Million | +26.16% |
| 2021-12-31 | $42.45 Million | +13.39% |
| 2020-12-31 | $37.43 Million | +1.28% |
| 2019-12-31 | $36.96 Million | -77.61% |
| 2018-12-31 | $165.09 Million | +33.45% |
| 2017-12-31 | $123.70 Million | -- |
About Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue… Read more